At least it does not kill people.
In one way, if it did have serious adverse effects then maybe they could enter the rodent extermination sector of the economy.
They have other products for epilepsy and dementia - but they claim that CimetreATM is their most "advanced" product - and it has no FDA approval yet. That does not say very much about their product lines.
"..demonstrated anti inflammatory and immuomodulating properties." - this is not unique in the world of inflammatory medications - and miost cold and flu/allergy medications can do this already.
Still, a step closer to FDA approval is something.
Key Highlights:
• MGC Pharma has completed the full pre-clinical rodents study panel for CimetrATM.
• The latest study, which was carried out at the Smart Assays laboratory in Israel,
included the development of bioanalytical methods and validations for further
pharmacokinetic analysis for CimetrATM.
• A study on chronic toxicity in rodents was also completed by Science in Action, in Israel,
monitoring the potential development of adverse effects from using CimetrATM.
• Histopathology demonstrated the full safety profile for CimetrATM across all study
dosage groups.
• The study results are an important step ahead of the submission to the US Food and
Drug Administration (FDA) for Investigational New Drug (IND) approval.
• No anomalies were observed in the biopsies, nor were any clinical or behavioural
adverse events recorded.
• CimetrATM is MGC Pharma’s proprietary Investigational Medicinal Product which in
previous clinical trials has demonstrated anti-inflammatory and immunomodulating
properties, and is MGC’s most clinically advanced product.
- Forums
- ASX - By Stock
- RGT
- Ann: Results of CimetrA bioanalytics pre-clinal trial
Ann: Results of CimetrA bioanalytics pre-clinal trial, page-4
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RGT (ASX) to my watchlist
(20min delay)
|
|||||
Last
32.0¢ |
Change
-0.005(1.54%) |
Mkt cap ! $15.48M |
Open | High | Low | Value | Volume |
32.0¢ | 34.0¢ | 32.0¢ | $1.734K | 5.316K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1666 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
34.0¢ | 1394 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1349 | 0.325 |
1 | 1654 | 0.320 |
2 | 4044 | 0.300 |
1 | 20000 | 0.250 |
1 | 2200 | 0.230 |
Price($) | Vol. | No. |
---|---|---|
0.290 | 100 | 1 |
0.300 | 250 | 1 |
0.320 | 1000 | 1 |
0.340 | 1394 | 1 |
0.360 | 12399 | 3 |
Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
Featured News
RGT (ASX) Chart |